Contact Us

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Immunotherapy is treatment that uses a certain part of a person’s immune system to fight diseases which is done by stimulating one’s own immune system to work harder to attack cancer cells or by giving immune system components, such as man-made immune system proteins. Immunotherapy includes treatments that work in different ways. Some boost the body’s immune system in a very general way and others help train the immune system to attack cancer cells specifically.

The global immuno-oncology market is estimated to account for US$ 12,993.8 Mn in terms of value in 2020 and is expected to reach US$ 37,783.6 Mn by the end of 2027.

Global Immuno-Oncology Market: Drivers

Increasing prevalence of cancer is expected to propel growth of the global immuno-oncology market over the forecast period. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S.

Moreover, R&D in monoclonal antibodies is also expected to boost demand for immuno-oncology. For instance, in January 2020, researchers from Universidade do Porto, Portugal, reported assessment of the role of O-glycosylation using glycoengineered gastric cancer models in the detection of CD44v9 – a major protein splice variant isoforms expressed in human gastrointestinal cancer cells—by monoclonal antibodies. 

Immune Checkpoint Inhibitors held dominant position in the global immuno-oncology market in 2019, accounting for 89.7% share in terms of value, followed by Immune System Modulators and Cancer Vaccines, respectively.

Figure 1. Global Immuno-Oncology Market Share (%), by Value, by Treatment Type, 2019

Immuno-Oncology Drugs  | Coherent Market Insights

Global Immuno-Oncology Market: Restraints

High R&D cost is expected to hinder growth of the global immuno-oncology market. The revolution in cancer treatment driven by molecular insights of genomics has moved decisively out of the lab and onto the market, but the R&D success is translating into staggering development costs for companies hoping to bring these innovative therapies to the market.

Moreover, several manufacturing challenges are adversely impacting product availability, thereby limiting the market growth. Limited organizations are able to offer manufacturing solutions, which drug developers seek in order to free up in-house capacity for clinical development material. Additionally, small biotech companies involved in this market rarely possess the infrastructure and capacity for commercial production.

request-sample

Immuno-Oncology Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2019: US$ 11,060.6 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 16.5% 2027 Value Projection: US$ 37,783.6 Mn
Geographies covered:
  • North America: U.S., Canada
  • Latin America: Brazil, Argentina, Mexico, Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, Rest of Middle East
  • Africa: South Africa, North Africa, Central Africa
Segments covered:
  • By Treatment Type:
    • Immune Checkpoint Inhibitors: PD-1, PD-L1, CTLA-4.
    • Immune System Modulators, Cancer Vaccines, Oncolytic Virus, Others.
  • By Disease Type: Melanoma, Lung Cancer, Blood Cancers, Renal Cell Carcinoma, Prostate Cancer, Bladder Cancer, Other Cancers.
  • By End User: Hospitals, Clinic, Ambulatory Surgical Centers.
Companies covered:

Amgen, Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, Dendreon Corporation (A Sanpower Group Company), F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer, Inc., Sanofi, Agilent Technologies Inc., Agenus Inc., Enzo Biochem, Inc., Lonza Group, Bio-Rad Laboratories, Inc., Avantor, Inc., Spring Bank Pharmaceuticals, Inc., and Ferring Pharmaceuticals

Growth Drivers:
  • High prevalence of cancer
  • Product launches
Restraints & Challenges:
  • High costs
  • Side effects

Global Immuno-Oncology Market: Opportunities  

R&D in CAR-T cell production is expected to offer lucrative growth opportunities for players in the global immuno-oncology market. For instance, in May 2020, researchers from University Hospital Heidelberg, Germany, reported that sufficient yield of lymphocytes for CAR-T cell production is feasible also for patients with low peripheral blood counts.

Moreover, increasing investment in immuno-oncology is also expected to aid in growth of the market. For instance, in July 2020, Agenus Inc., an immuno-oncology company, raised US$ 35 million.

The global immuno-oncology market was valued at US$ 11,060.6 Mn in 2019 and is forecast to reach a value of US$ 37,783.6 Mn by 2027 at a CAGR of 16.5% between 2020 and 2027.

Figure 2. Global Immuno-Oncology Market Value (US$ Mn), and Y-o-Y Growth (%), 2019-2027

Immuno-Oncology Drugs  | Coherent Market Insights

Market Trends/Key Takeaways

Major players in the global immuno-oncology market are focused on approval and launch of new products to expand their product portfolio. For instance, in March 2019, F. Hoffmann-La Roche Ltd. received the U.S. Food and Drug Administration (FDA) approval of the VENTANA PD-L1 (SP142) Assay, as the first companion diagnostic to aid in identifying triple-negative breast cancer (TNBC) patients eligible for treatment with the Roche cancer immunotherapy Tecentriq (atezolizumab) plus chemotherapy.

Major players in the market are also focused on expanding their production capacities. For instance, in August 2018, Enzo Biochem, Inc. announced that it has entered into an agreement to purchase a commercial facility with nearly 36,000 square feet in Farmingdale, NY, to advance its diagnostic and therapeutic growth strategy. The facility is expected to enhance the company’s ability to produce and distribute its growing portfolio of molecular assays, immunohistochemistry, immunoassays and immuno-oncology products and services.

Global Immuno-Oncology Market: Competitive Landscape

Major players operating in the global immuno-oncology market include, Amgen, Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, Dendreon Corporation (A Sanpower Group Company), F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer, Inc., Sanofi, Agilent Technologies Inc., Agenus Inc., Enzo Biochem, Inc., Lonza Group, Bio-Rad Laboratories, Inc., Avantor, Inc., Spring Bank Pharmaceuticals, Inc., and Ferring Pharmaceuticals.

Global Immuno-Oncology Market: Key Developments

Major players in the global immuno-oncology market are focused on adopting collaboration and partnership strategies to enhance their market share. For instance, in November 2019, Avantor, Inc. collaborated with National Institute for Bioprocessing Research and Training, Ireland, to address downstream issues with buffer preparation when producing monoclonal antibodies.

Major players in the market are also focused on approval and launch of new products to expand their product portfolio. For instance, in July 2019, Bio-Rad Laboratories, Inc. launched its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for immunotherapy research.

Immuno-oncology involves use of patients’ immune system to fight against cancer. Immuno-oncology uses novel immunotherapies that boost the immune system of patients. These therapies target the immune system of the body instead of the tumors and enable the immune system to recognize and target cancer cells. Immuno-oncology does not affect the functioning of healthy cells as opposed to conventional therapies such as chemotherapy and radiation therapy. Long term response can be generated with the help of these therapies as they provide long-lasting memory to the immune system. Immune system adapts to the cancer over time and provides long term response to the cancer. Immuno-Oncology therapy work against a wide variety of cancer, which include non-small cell lung cancer, acute myeloid leukemia, lymphoma, multiple myeloma, breast cancer, and others.

Restraints of the Global Immuno-Oncology Market

Major factors hampering the growth of the immuno-oncology market during the forecast period constitutes of high costs. High cost of immuno-oncology therapies, which is unaffordable to low and middle class population is restraining growth of the market. For instance Keytruda (Pembrolizumab), a monoclonal antibody for the treatment of various types of cancer costs around US$ 2,250 for a vial of 50 mg.

Key features of the study:

  • This report provides in-depth analysis of the global immuno-oncology market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2019–2027), considering 2018, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
  • It profiles leading players in the global immuno-oncology market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Allergan, Inc., Novartis AG, Valeant Pharmaceuticals International, Inc., Galapagos, EyePoint Pharmaceuticals, Inc., Clearside Biomedical, Inc., AbbVie Inc., Tarsius Pharma, Eyegate Pharmaceuticals, Inc., Alimera Sciences Inc., and pSivida Corp.
  • Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global immuno-oncology market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.

Detailed Segmentation

  • Global Immuno-Oncology Market, By Treatment Type:
    • Immune Checkpoint Inhibitors
      • PD-1
      • PD-L1
      • CTLA-4
    • Immune System Modulators
    • Cancer Vaccines
    • Oncolytic Virus
    • Others
  • Global Immuno-Oncology Market, By Disease Type:
    • Melanoma
    • Lung Cancer
    • Blood Cancers
    • Renal Cell Carcinoma
    • Prostate Cancer
    • Bladder Cancer
    • Other Cancers
  • Global Immuno-Oncology Market, By End User:
    • Hospitals
    • Clinics
    • Ambulatory Surgical Centers
  • Global Immuno-Oncology Market, By Geography:
    • North America
      • By Treatment Type
        • Immune Checkpoint Inhibitors
          • PD-1
          • PD-L1
          • CTLA-4
        • Immune System Modulators
        • Cancer Vaccines
        • Oncolytic Virus
        • Others
      • By Disease Type
        • Melanoma
        • Lung Cancer
        • Blood Cancers
        • Renal Cell Carcinoma
        • Prostate Cancer
        • Bladder Cancer
        • Other Cancers
      • By End User
        • Hospitals
        • Clinics
        • Ambulatory Surgical Centers
      • By Country:
        • U.S.
        • Canada
    • Europe
      • By Treatment Type
        • Immune Checkpoint Inhibitors
          • PD-1
          • PD-L1
          • CTLA-4
        • Immune System Modulators
        • Cancer Vaccines
        • Oncolytic Virus
        • Others
      • By Disease Type
        • Melanoma
        • Lung Cancer
        • Blood Cancers
        • Renal Cell Carcinoma
        • Prostate Cancer
        • Bladder Cancer
        • Other Cancers
      • By End User
        • Hospitals
        • Clinics
        • Ambulatory Surgical Centers
      • By Country:
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Treatment Type
        • Immune Checkpoint Inhibitors
          • PD-1
          • PD-L1
          • CTLA-4
        • Immune System Modulators
        • Cancer Vaccines
        • Oncolytic Virus
        • Others
      • By Disease Type
        • Melanoma
        • Lung Cancer
        • Blood Cancers
        • Renal Cell Carcinoma
        • Prostate Cancer
        • Bladder Cancer
        • Other Cancers
      • By End User
        • Hospitals
        • Clinics
        • Ambulatory Surgical Centers
      • By Country:
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • By Treatment Type
        • Immune Checkpoint Inhibitors
          • PD-1
          • PD-L1
          • CTLA-4
        • Immune System Modulators
        • Cancer Vaccines
        • Oncolytic Virus
        • Others
      • By Disease Type
        • Melanoma
        • Lung Cancer
        • Blood Cancers
        • Renal Cell Carcinoma
        • Prostate Cancer
        • Bladder Cancer
        • Other Cancers
      • By End User
        • Hospitals
        • Clinics
        • Ambulatory Surgical Centers
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East:
      • By Treatment Type
        • Immune Checkpoint Inhibitors
          • PD-1
          • PD-L1
          • CTLA-4
        • Immune System Modulators
        • Cancer Vaccines
        • Oncolytic Virus
        • Others
      • By Disease Type
        • Melanoma
        • Lung Cancer
        • Blood Cancers
        • Renal Cell Carcinoma
        • Prostate Cancer
        • Bladder Cancer
        • Other Cancers
      • By End User
        • Hospitals
        • Clinics
        • Ambulatory Surgical Centers
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Treatment Type
        • Immune Checkpoint Inhibitors
          • PD-1
          • PD-L1
          • CTLA-4
        • Immune System Modulators
        • Cancer Vaccines
        • Oncolytic Virus
        • Others
      • By Disease Type
        • Melanoma
        • Lung Cancer
        • Blood Cancers
        • Renal Cell Carcinoma
        • Prostate Cancer
        • Bladder Cancer
        • Other Cancers
      • By End User
        • Hospitals
        • Clinics
        • Ambulatory Surgical Centers
      • By Country/Region:
        • Central Africa
        • South Africa
        • North Africa
  • Company Profiles
    • Amgen, Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • AstraZeneca Plc
    • Bristol-Myers Squibb Company
    • Dendreon Corporation (A Sanpower Group Company)
    • F. Hoffmann-La Roche Ltd.
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer, Inc.
    • Sanofi S.A.
    • Ferring Pharmaceuticals
    • Enzo Biochem, Inc.

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Treatment Type
      • Market Snippet, By Disease Type
      • Market Snippet, By End User
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Developments
    • Regulatory Scenario
    • PEST Analysis
    • COVID-19 Impact Analysis
  4. Global Immuno-Oncology Market, By Treatment Type, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • Immune Checkpoint Inhibitors
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
        • PD-1
        • PD-L1
        • CTLA-4
    • Immune System Modulators
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
    • Cancer Vaccines
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
    • Oncolytic Virus
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
  5. Global Immuno-Oncology Market, By Disease Type, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • Melanoma
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Lung Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Blood Cancers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Renal Cell Carcinoma
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Prostate Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Bladder Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  6. Global Immuno-Oncology Market, By End User, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • Hospitals
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Clinics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Ambulatory Surgical Centers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  7. Global Immuno-Oncology Market, By Regions, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • North Africa
        • Central Africa
        • South Africa
  8. Competitive Landscape
    • Company Profiles
      • Allergan, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • AstraZeneca Plc
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Bristol-Myers Squibb Company
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Dendreon Corporation (A Sanpower Group Company)
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • F. Hoffmann-La Roche Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Merck & Co., Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Novartis AG
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Pfizer, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Sanofi S.A.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Ferring Pharmaceuticals
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Enzo Biochem, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 36 market data tables and 25 figures on “Immuno-Oncology Market – Global forecast to 2027.

Frequently Asked Questions

The global immuno-oncology market was valued at US$ 11,060.6 Mn in 2019 and is forecast to reach a value of US$ 37,783.6 Mn by 2027 at a CAGR of 16.5% between 2020 and 2027.
Major factor driving the growth of global immuno-oncology market during the forecast period include high prevalence of cancer, and product launches.
Major factors hampering the growth of the immuno-oncology market during the forecast period constitutes of high costs, and side effects associated with immuno therapies.
Immune Checkpoint Inhibitors held dominant position in the global immuno-oncology market in 2019.
North America Immuno-Oncology market is expected to generate the highest revenue during the forecast period.
Some of the key players operating in the market are Amgen, Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, Dendreon Corporation (A Sanpower Group Company), F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer, Inc., Sanofi, Agilent Technologies Inc., Agenus Inc., Enzo Biochem, Inc., Lonza Group, Bio-Rad Laboratories, Inc., Avantor, Inc., Spring Bank Pharmaceuticals, Inc., and Ferring Pharmaceuticals.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner